New treatment option for PE

In this large trial of patients with acute symptomatic PE, they all received 5-10 days of LMWH (1mg/kg/dose BID), then 3-6 months of either adjusted dose warfarin, or weekly idrabiotaparinux; the new drug had equivalent risk of recurrent VTE, but lower risk of bleeding at 99 days follow up. This convenient new drug may be an attractive alternative to warfarin, pending FDA approval, and depending on price (abstract)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment